Kisspeptin regulation of genes involved in cell invasion and angiogenesis in first trimester human trophoblast cells

The precise regulation of extravillous trophoblast invasion of the uterine wall is a key process in successful pregnancies. Kisspeptin (KP) has been shown to inhibit cancer cell metastasis and placental trophoblast cell migration. In this study primary cultures of first trimester human trophoblast cells have been utilized in order to study the regulation of invasion and angiogenesis-related genes by KP. Trophoblast cells were isolated from first trimester placenta and their identity was confirmed by immunostaining for cytokeratin-7. Real-time quantitative RT-PCR demonstrated that primary trophoblast cells express higher levels of GPR54 (KP receptor) and KP mRNA than the trophoblast cell line HTR8Svneo. Furthermore, trophoblast cells also expressed higher GPR54 and KP protein levels. Treating primary trophoblast cells with KP induced ERK1/2 phosphorylation, while co-treating the cells with a KP antagonist almost completely blocked the activation of ERK1/2 and demonstrated that KP through its cognate GPR54 receptor can activate ERK1/2 in trophoblast cells. KP reduced the migratory capability of trophoblast cells in a scratch-migration assay. Real-time quantitative RT-PCR demonstrated that KP treatment reduced the expression of matrix metalloproteinase 1, 2, 3, 7, 9, 10, 14 and VEGF-A, and increased the expression of tissue inhibitors of metalloproteinases 1 and 3. These results suggest that KP can inhibit first trimester trophoblast cells invasion via inhibition of cell migration and down regulation of the metalloproteinase system and VEGF-A.The South African MRC and the University of Cape Town.http://www.plosone.orgam201

Kisspeptin regulation of genes involved in cell invasion and angiogenesis in first trimester human trophoblast cells

The precise regulation of extravillous trophoblast invasion of the uterine wall is a key process in successful pregnancies. Kisspeptin (KP) has been shown to inhibit cancer cell metastasis and placental trophoblast cell migration. In this study primary cultures of first trimester human trophoblast cells have been utilized in order to study the regulation of invasion and angiogenesis-related genes by KP. Trophoblast cells were isolated from first trimester placenta and their identity was confirmed by immunostaining for cytokeratin-7. Real-time quantitative RT-PCR demonstrated that primary trophoblast cells express higher levels of GPR54 (KP receptor) and KP mRNA than the trophoblast cell line HTR8Svneo. Furthermore, trophoblast cells also expressed higher GPR54 and KP protein levels. Treating primary trophoblast cells with KP induced ERK1/2 phosphorylation, while co-treating the cells with a KP antagonist almost completely blocked the activation of ERK1/2 and demonstrated that KP through its cognate GPR54 receptor can activate ERK1/2 in trophoblast cells. KP reduced the migratory capability of trophoblast cells in a scratch-migration assay. Real-time quantitative RT-PCR demonstrated that KP treatment reduced the expression of matrix metalloproteinase 1, 2, 3, 7, 9, 10, 14 and VEGF-A, and increased the expression of tissue inhibitors of metalloproteinases 1 and 3. These results suggest that KP can inhibit first trimester trophoblast cells invasion via inhibition of cell migration and down regulation of the metalloproteinase system and VEGF-A

Neonatal presentation of a child with Liddle syndrome, South Africa

DATA AVAILABILITY : Data supporting the findings of this study are available within the article.INTRODUCTION : Liddle syndrome is an autosomal dominantly inherited disorder usually arising from single mutations of the genes that encode for the alpha, beta and gamma epithelial sodium channel (ENaC) subunits. This leads to refractory hypertension, hypokalaemia, metabolic alkalosis, hyporeninaemia and hypoaldosteronism, through over-activation of the ENaC. CASE PRESENTATION : We describe a 5-day old neonate who presented with severe hypernatraemic dehydration requiring admission to Steve Biko Academic Hospital in South Africa in 2012. Further evaluation revealed features in keeping with Liddle syndrome. Two compound heterozygous mutations located at different subunits encoding the ENaC were detected following genetic sequencing done in 2020. The severe clinical phenotype observed here could be attributed to the synergistic effect of these known pathological mutations, but may also indicate that one of the other variants detected has hitherto undocumented pathological effects. MANAGEMENT AND OUTCOME : This child’s treatment course was complicated by poor adherence to therapy, requiring numerous admissions over the years. Adequate blood pressure control was achieved only after the addition of amiloride at the end of 2018, which raised the suspicion of an ENaC abnormality. CONCLUSION : To our knowledge, this is the first Liddle syndrome case where a combined effect from mutations resulted in severe disease. This highlights the importance of early recognition and management of this highly treatable genetic disease to prevent the grave sequelae associated with long-standing hypertension. Whole exome sequencing may assist in the detection of known mutations, but may also unveil new potentially pathological variants. WHAT THIS STUDY ADDS : This study highlights the importance of developing a high index of suspicion of tubulopathy such as Liddle syndrome for any child presenting with persistent hypertension associated with hypokalaemic metabolic alkalosis.http://www.ajlmonline.orgChemical PathologyPaediatrics and Child Healt

List of genes downregulated in the Human Extracellular Matrix and Adhesion Molecules gene array.

<p>List of genes downregulated in the Human Extracellular Matrix and Adhesion Molecules gene array.</p

List of genes upregulated in the Human Extracellular Matrix and Adhesion Molecules gene array.

<p>List of genes upregulated in the Human Extracellular Matrix and Adhesion Molecules gene array.</p

Characterization of primary cultures of first trimester trophoblast cells.

<p>Staining of primary cultures of isolated first trimester trophoblast cells. Top row, <b>s</b>taining with DAPI (blue) which labels cell nuclei, anti-cytokeratin-7 (CYT-7, red), anti-GPR54 (green) and the merge of staining with anti-cytokeratin-7 (red) and anti-GPR54 (green). Middle row, <b>s</b>taining with DAPI (blue), anti-vimentin (VIM, red), anti-GPR54 (green) and the merge of staining with anti-vimentin (red) and anti-GPR54 (green). Bottom row, staining with DAPI (blue), isotype matched mouse and rabbit IgG as negative controls and their merge. Scale bar indicates 200 µm.</p

KP regulates expression of VEGF-A, but not of ANGPTL4.

<p>Trophoblast cells were either not treated (white bars) or treated with 100 nM KP (light grey bars), 1 µM KP antagonist (p356) (dark grey bars) or both treatments in combination (black bars) for 48 h. RNA was extracted and expression of VEGF-A <b>(A)</b> and ANGPTL4 <b>(B)</b> was analyzed by qPCR. Error bars represent SEM. ANOVA test p<0.05, columns with different letters represent statistically different values, n.s.  =  no significant difference.</p

Expression of GPR54 and KP and KP induction of ERK in primary trophoblast cells.

<p>Relative mRNA expression levels of GPR54 <b>(A)</b> and KP <b>(B)</b> in HTR8 cells (white bars) and trophoblast cells (black bars). Protein expression of GPR54 <b>(C)</b> and KP-145 and KP-54 <b>(D)</b> in HTR8 cells and trophoblast cells. β-actin was used as a loading control. <b>(E)</b> HTR8 and trophoblast cells were treated for 10 min with vehicle (-), 1 µM KP antagonist (p356), 100 nM KP or both treatments (KP + p356) in combination in serum-free medium. Phospho- and total ERK1/2 protein levels were determined by Western Blot. <b>(F)</b> Quantification of Western Blots for phospho- and total ERK1/2 expression (n = 3). Error bars represent SEM. Statistical significance was tested by ANOVA, columns with different letters represent statistically different values, p<0.05, while same letters indicates no significant difference, p>0.05.</p

KP inhibits trophoblast migration.

<p><b>(A)</b> Images of the scratch migration assay performed on trophoblast cells treated for 48(-), 100 nM KP, 1 µM KP antagonist (p356) or both treatments (KP + p356) in combination. Images were taken immediately after performing the scratch (0 h) and 48 hours later (48 h). <b>(B)</b> Quantification of the relative migration of untreated trophoblast cells (white bar) and trophoblast cells treated with KP (light grey bar), p356 (dark grey bar) or KP + p356 (black bar) (n = 6). ANOVA test p<0.05, columns with different letters represent statistically different values, while same letters indicates no significant difference. <b>(C)</b> Staining of the migrated cells with DAPI (blue), anti-GPR54 (green) and the merge of staining. Scale bar indicates 200 µm.</p

KP supresses expression of MMPs and induces expression of TIMPs.

<p>Trophoblast cells were either not treated (white bars) or treated with 100 nM KP (light grey bars), 1 µM KP antagonist (p356) (dark grey bars) or both treatments in combination (black bars) for 48 h. RNA was extracted and expression of MMP1 <b>(A)</b>, MMP2 <b>(B)</b>, MMP3 <b>(C)</b>, MMP7 <b>(D)</b>, MMP9 <b>(E)</b>, MMP10 <b>(F)</b>, MMP14 <b>(G)</b>, MMP16 <b>(H)</b>, TIMP1 <b>(I)</b>, TIMP2 <b>(J)</b> and TIMP3 <b>(K)</b> was analyzed by qPCR. Error bars represent SEM. ANOVA test p<0.05, columns with different letters represent statistically different values, n.s.  =  no significant difference.</p